Fraizeron 150mg/ml Inj. 1`s

Doctors prescribe it as a subcutaneous injection given under the skin at scheduled intervals.

Fraizeron 150mg/ml Injection Ingredients and Usage

Fraizeron 150mg/ml Injection contains secukinumab, a fully human monoclonal antibody belonging to the interleukin-17A inhibitor drug class. Doctors prescribe it for moderate to severe plaque psoriasis in adults when systemic therapy is appropriate.

Fraizeron 150mg/ml Injection also treats active psoriatic arthritis and active ankylosing spondylitis, an inflammatory condition affecting the spine. It is given as a subcutaneous injection into the thigh, upper arm, or abdomen, following a specific loading and maintenance schedule set by the prescribing doctor.

How Does Fraizeron 150mg/ml Injection Work?

Secukinumab selectively binds to interleukin-17A, a cytokine that plays a central role in the inflammatory pathways driving psoriasis, psoriatic arthritis, and ankylosing spondylitis. By binding this cytokine, secukinumab prevents it from interacting with its receptor.

This blockade reduces the release of downstream inflammatory proteins responsible for the skin scaling, joint pain, and spinal inflammation seen in these conditions. Fraizeron 150mg/ml Injection typically produces a rapid reduction in inflammatory symptoms compared to older systemic therapies.

Fraizeron 150mg/ml Injection Side Effects

Fraizeron 150mg/ml Injection is generally well tolerated, with most side effects mild to moderate.

• Common cold-like symptoms and nasal congestion

• Upper respiratory tract infections

• Diarrhea

• Headache

• Injection site reactions

• Fatigue

Warnings

• Fraizeron 150mg/ml Injection increases the risk of infections; patients should be evaluated for active or latent tuberculosis before starting treatment, and monitored for signs of infection throughout.

• The medicine is contraindicated in patients with active infection, active tuberculosis, hepatitis B, hepatitis C, or HIV.

• New onset or worsening inflammatory bowel disease, including Crohn's disease and ulcerative colitis, has occurred in patients treated with secukinumab; caution is needed in patients with a personal or family history of IBD.

• Serious hypersensitivity reactions, including anaphylaxis and urticaria, have been reported; stop treatment immediately and seek emergency care if these occur.

• Fraizeron 150mg/ml Injection is contraindicated in patients with known hypersensitivity to secukinumab or to latex.

• Avoid live vaccines during treatment, since secukinumab suppresses immune pathways involved in vaccine response.

• Discuss risks and benefits with a doctor before use during pregnancy or breastfeeding, since safety data in these groups are limited.

Fraizeron 150mg/ml Injection Storage Conditions

Store Fraizeron 150mg/ml Injection refrigerated between 2°C and 8°C, and do not freeze. Keep the vial in its original carton to protect it from light. Before use, allow the medicine to reach room temperature for 15 to 30 minutes, but do not leave it out for more than one hour. Store this medicine out of reach of children.